Category: BioTech

Analysis, BioTech, Diversified Tech, Finance, Mergers & Acquisitions, Semiconductors, Services Sector, Software, Tech IPO, Venture Capital

Fee Waivers and Weaker Fund Flows Affect Federated’s First- Quarter Results; No Change to FVE

There was nothing in the first-quarter results from narrowmoat Federated Investors FII that would alter our longterm view on the firm. With the company’s assets under management (AUM) so heavily skewed toward money market funds, Federated continues to be affected not only by historically low interest rates (which require the use of fee waivers to keep fund costs from driving yields into negative territory) but … Continue reading Fee Waivers and Weaker Fund Flows Affect Federated’s First- Quarter Results; No Change to FVE

John MeadyLeave a comment
Analysis, BioTech, Commodities, Diversified Tech, Finance, Mergers & Acquisitions, Semiconductors, Services Sector, Software, Tech IPO, Venture Capital

DTE`s 1Q Earnings Surge on Colder Weather and Lower Benefit Costs

We will be maintaining our $55 fair value estimate and stable narrow moat trend for DTE Energy DTE after the company announced first-quarter earnings that were driven higher primarily by much colder weather for both the gas and the electric utilities. During the quarter, DTE earned $1.34 per share versus $0.91 per share for the prior-year period. While rates at the gas utility and lower … Continue reading DTE`s 1Q Earnings Surge on Colder Weather and Lower Benefit Costs

John MeadyLeave a comment
BioTech, Finance

Active Biotech Stocks: Kite Pharma Drug

Kite Pharma, Inc (KITE) announced the publication of positive results from an ongoing phase I-IIa study on KTE-C19 in patients suffering from aggressive non-Hodgkin’s lymphoma in the Aug 25, 2014 issue of the American Society of Clinical Oncology’s Journal of Clinical Oncology. In the phase I-II study, KTE-C19 achieved 92% overall objective response rate. According to Kite Pharma, out of 13 patients with advanced B-cell … Continue reading Active Biotech Stocks: Kite Pharma Drug

Richard Atkins
Biotech stock market news
BioTech, Finance

Biotech Stocks: Amicus Therapeutics (FOLD) Soars High After Positive Results

Shares of Amicus Therapeutics (FOLD) soared 20.4% after the company announced positive data from its second phase III study (Study 012) on the oral small molecule chaperone migalastat HCl in Fabry patients with amenable mutations. The phase III study is evaluating the use of oral migalastat to standard-of-care enzyme replacement therapies (ERTs) − Sanofi’s (SNY) Fabrazyme and Shire’s (SHPG) Replagal − for Fabry disease. Eighteen-month … Continue reading Biotech Stocks: Amicus Therapeutics (FOLD) Soars High After Positive Results

Richard Atkins
Analysis, BioTech, Commodities, Diversified Tech, Finance, Mergers & Acquisitions, Semiconductors, Services Sector, Software, Tech IPO, Venture Capital

Autoliv Reports 1Q Results, Beats Street Consensus by $0.09; Maintaining our $80 FVE

No-moat, positive-moat-trend rated Autoliv ALV reported first-quarter earnings per share before special items of $1.32, $0.09 ahead of the Street consensus of $1.23. Even so, owing to lackluster European new-car demand and Autoliv’s European customers’ inventory corrections, the $1.32 first-quarter EPS were down $0.24 from $1.56 a year ago. However, management favorably tweaked its full-year 2013 guidance, slightly raising its expectations for revenue growth of … Continue reading Autoliv Reports 1Q Results, Beats Street Consensus by $0.09; Maintaining our $80 FVE

John MeadyLeave a comment
BioTech, Finance

Biotech Stocks: The Consequences of Intermune Takeover

Roche’s (RHHBY) $8.3 billion deal, announced over the weekend, to take over biotech firm InterMune (ITMN) triggered significant stock price appreciation in many mid-cap firms in the space on Aug 25. Switzerland-based Roche is looking to strengthen its respiratory portfolio through the impending InterMune buy. The offer price of $74.00 per share represents a premium of 37.5% to InterMune’s closing price on Aug 22, 2014. … Continue reading Biotech Stocks: The Consequences of Intermune Takeover

Richard Atkins